OpenArc Corporate Advisory’s Bristol-Myers Squibb BMY Stock Holding History

OpenArc Corporate Advisory’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.78M	Buy	29,272 +16,149	+123%	+$941K	0.03%	258
2025 Q4	$708K	Buy	+13,123	New	+$631K	0.01%	343

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OpenArc Corporate Advisory's BMY Position: Q1 2026 in Review

OpenArc Corporate Advisory increased its Bristol-Myers Squibb (BMY) stake by 123% in Q1 2026, buying an estimated $941K and bringing the position to 29,272 shares worth $1.78M. The position accounts for 0.03% of the portfolio, ranked #258.

OpenArc Corporate Advisory first reported a position in BMY in Q4 2025 and has held it in 2 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

OpenArc Corporate Advisory held 29,272 shares of Bristol-Myers Squibb worth $1.78M as of Q1 2026.
OpenArc Corporate Advisory bought 16,149 Bristol-Myers Squibb shares in Q1 2026, an estimated $941K.
Bristol-Myers Squibb made up 0.03% of OpenArc Corporate Advisory's portfolio in Q1 2026, its #258 holding.
OpenArc Corporate Advisory first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 2 quarters since.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.